Prevalence Of Genital HPV Infection In Males Following Introduction Of Universal Male HPV Vaccination
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
As Australia is the first and only country to implement a free universal school based male human papillomavirus (HPV) vaccination program (in 2013), this project has the unique opportunity to be first to study to assess the effectiveness of the male HPV vaccination program in Australia by measuring a change in the prevalence of HPV among young (aged 17-20) heterosexual and homosexual men following the implementation of the vaccination program.
Reducing Disparities In Cervical Cancer Incidence For Aboriginal And Torres Strait Islander Women Through Screening And Vaccination
Funder
National Health and Medical Research Council
Funding Amount
$329,768.00
Summary
This program of research will aim to reduce cervical cancer incidence for Indigenous women by developing and trialling health systems interventions to increase cervical screening participation and HPV vaccination coverage. This research will be led by an Indigenous researcher with Indigenous people and for Indigenous people.
Serological Responses To Anal HPV Infection: Characterising The Natural History Of Anal HPV
Funder
National Health and Medical Research Council
Funding Amount
$220,506.00
Summary
Human papillomavirus (HPV) causes 90% of anal cancer. Anal cancer rates are 20-100 times higher in gay men than other men. The natural history of anal HPV infection and progression to cancer is not completely understood. This study measuring antibodies to HPV will be part of the ongoing Study of the Prevention of Anal Cancer. We aim to show 1) if infection provides any immunity, which will inform HPV vaccination of older gay men and 2) whether antibodies could be used as a marker of cancer risk.
Centre For Research Excellence In Cervical Cancer Control (C4)
Funder
National Health and Medical Research Council
Funding Amount
$2,486,383.00
Summary
Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.
Identifying And Addressing Gaps In Australia’s Adolescent HPV Vaccination Program
Funder
National Health and Medical Research Council
Funding Amount
$689,723.00
Summary
Australia was the first country to implement a national vaccination program for human papillomavirus (HPV) which is the primary cause of cervical cancer. However national vaccination coverage remains suboptimal at 77% in girls. Through a partnership between researchers and health departments (Tasmania, Western Australia and New South Wales) we will conduct research to determine barriers to vaccination and evaluate the cost and impact of innovative strategies to increase vaccination coverage.
A Vulvar Cancer Cluster Caused By Genetic Susceptibility: Investigating The Genetic Mechanism.
Funder
National Health and Medical Research Council
Funding Amount
$1,154,342.00
Summary
Cancer of the vulva is 70 times more common in young Aboriginal women in Arnhem Land than in other women. Human Papillomavirus (HPV), which also causes cervical cancer, is the usual cause of this cancer; initial investigations have found that HPV is present in these cancers but is not the reason for the excessive incidence. This study will investigate inherited risk factors contributing to the development of this disease in this population.